| Literature DB >> 23762173 |
Chuntong Li1, Fengmin Xi, Junling Mi, Zhijun Wu, Wansheng Chen.
Abstract
A pair of new 3,4;9,10-seco-cycloartane type triterpenoid stereoisomerides: 24R,25-dihydroxy-3,4;9,10-seco-4(28)-cycloarten-10,3-olide (1) named Illiciumolide A and 24S,25-dihydroxy-3,4;9,10-seco-4(28)-cycloarten-10,3-olide (2) named Illiciumolide B were isolated from the stem bark of Illicium difengpi, as well as five known biogenetically related triterpenoids, including sootepin E (3), betulinic acid (4), lupeol (5), (all-Z)-1,5,9,13,17,21-hexamethyl-1,5,9,13,17,21-cyclotertracosahexaene (6), and (all-E)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene (7). The structures of two new compounds were determined on the basis of spectroscopic analysis including 1D-, 2D-NMR, and MS techniques. Two assays were conducted: inhibition of tumor necrosis factor-alpha (TNF-α) and inhibition of nuclear factor kappa B (NF-κB) in RAW264. 7 cells induced by lipopolysaccharide (LPS). It was observed that compounds 1, 2 and 7 showed significant inhibition of TNF-α production and NF-κB release. The molecule docking results showed that compounds 1 and 2 got high fitness scores with dual specificity mitogen-activated protein kinase kinase 1 (MPKK1), whose activation plays a pivotal role between TNF-α and activation of NF-κB. The anti-HIV-1 potency of compounds 1-5 was also discussed, in addition to the results of computer-aided screening for targets.Entities:
Year: 2013 PMID: 23762173 PMCID: PMC3671308 DOI: 10.1155/2013/942541
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
1H-NMR (600 MHz) and 13C-NMR (150 MHz) data for compounds 1 and 2 (CDCl3, δ H in ppm, J in Hz).
| Position |
|
| ||
|---|---|---|---|---|
|
|
|
|
| |
| 1 | 31.5, CH2 | 2.33 (m, Hb-1) | 31.5, CH2 | 2.30–2.36 (m, Hb-1) |
| 2 | 29.6, CH2 | 2.41–2.48 (m, Ha-2) | 29.6, CH2 | 2.42–2.48 (m, Ha-2) |
| 3 | 177.3, qC | — | 177.3, qC | — |
| 4 | 146.6, qC | — | 146.6, qC | — |
| 5 | 54.8, CH | 2.54 (d, 9.6, H-5) | 54.8, CH | 2.56 (d, 9.8, H-5) |
| 6 | 31.4, CH2 | 1.65–1.70 (m, Ha-6) | 31.4, CH2 | 1.61–1.67 (m, Ha-6) |
| 7 | 30.5, CH2 | 1.46–1.51 (m, Ha-7) | 30.5, CH2 | 1.41–1.46 (m, Ha-7) |
| 8 | 48.4, CH | 1.43 (dd, 3.2, 7.0, H-8) | 48.4, CH | 1.42–1.47 (m, H-8) |
| 9 | 31.7, CH | 1.90 (td, 7.4, 14.0, H-9) | 31.7, CH | 1.85–1.92 (m, H-9) |
| 10 | 91.7, qC | — | 91.7, qC | — |
| 11 | 29.6, CH2 | 1.23 (m, Ha-11) | 29.6, CH2 | 1.46 (m, Ha-11) |
| 12 | 32.7, CH2 | 1.61–1.64 (m, Ha-12) | 32.7, CH2 | 1.61–1.64 (m, Ha-12) |
| 13 | 45.5, qC | — | 45.5, qC | — |
| 14 | 49.2, qC | — | 49.2, qC | — |
| 15 | 33.3, CH2 | 1.06–1.14 (m, Ha-15) | 34.0, CH2 | 0.97–1.02 (m, Ha-15) |
| 16 | 27.9, CH2 | 1.37–1.42 (m, Ha-16) | 27.8, CH2 | 1.47 (m, Ha-16) |
| 17 | 51.0, CH | 1.49–1.53 (m, H-17) | 50.9, CH | 1.49–1.55 (m, H-17) |
| 18 | 14.7, CH3 | 0.80 (s, H3-18) | 14.7, CH3 | 0.80 (s, H3-18) |
| 19 | 49.2, CH2 | 1.64–1.70 (m, Ha-19) | 49.2, CH2 | 1.64–1.70 (m, Ha-19) |
| 20 | 35.9, CH | 1.37–1.47 (m, H-20) | 36.4, CH | 1.51–1.55 (m, H-20) |
| 21 | 18.3, CH3 | 0.86 (d, 7.22, H3-21) | 18.6, CH3 | 0.88 (d, 6.5, H3-21) |
| 22 | 33.1, CH2 | 1.13–1.20 (m, Ha-22) | 33.3, CH2 | 1.13–1.20 (m, Ha-22) |
| 23 | 28.3, CH2 | 1.36 (m, Ha-23) | 28.6, CH2 | 1.36 (m, Ha-23) |
| 24 | 78.7, CH | 3.31 (t, 6.2, H-24) | 79.6, CH | 3.27 (dd, 9.5, 1.6, H-24) |
| 25 | 73.2, qC | — | 73.2, qC | — |
| 26 | 23.2, CH3 | 1.14 (s, H3-26) | 23.2, CH3 | 1.15 (s, H3-26) |
| 27 | 26.6, CH3 | 1.19 (s, H3-27) | 26.5, CH3 | 1.21 (s, H3-27) |
| 28 | 16.6, CH3 | 0.83 (s, H3-28) | 16.7, CH3 | 0.84 (s, H3-28) |
| 29 | 22.6, CH3 | 1.76 (s, H3-29) | 22.6, CH3 | 1.77 (s, H3-29) |
| 30 | 115.0, CH2 | 4.80 (s, Ha-30) | 115.0, CH2 | 4.81 (s, Ha-30) |
Figure 2Key 1H-1H COSY (bold lines) and HMBC (H→C) correlations of compound 1.
Figure 3Key NOE correlations of compound 1.
Figure 1Structures of compounds 1–7.
Figure 4Inhibitory rate of TNF-α production from LPS-stimulated RAW 264.7 cells by compounds 1–7 at a concentration of 25 mg/mL. **P < 0.01 for TNF-α levels in RAW 264.7 cells treated with LPS in the presence of the test compounds versus that in the absence of the test compounds.
Figure 5Inhibitory rate of NF-κB production from LPS-stimulated RAW 264.7 cells by (a) Compounds 6-7 at three concentrations 90 μg/mL, 30 μg/mL, and 10 μg/mL. (b) Compounds 1–5 at three concentrations 20 μg/mL, 10 μg/mL, and 5 μg/mL. *P < 0.05 and **P < 0.01 for TNF-α levels in RAW 264.7 cells treated with LPS in the presence of the test compounds versus that in the absence of the test compounds.
Screening anti-inflammation targets over molecule docking of compounds 1–5.
| Compound number | Molecules docking results | ||
|---|---|---|---|
| Target name | Fit score | Norm fit score | |
| Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) | 4.111 | 0.4567 | |
| Glucocorticoid receptor (GR) | 4.010 | 0.5012 | |
| Prothrombin | 3.843 | 0.4271 | |
|
| Alpha-1-antitrypsin | 3.834 | 0.6390 |
| Glycogen synthase kinase-3 beta | 3.786 | 0.5409 | |
| ADAM 17 | 3.726 | 0.9315 | |
| Tyrosine-protein kinase SYK | 3.712 | 0.6187 | |
| Protein kinase C theta type | 3.701 | 0.5287 | |
|
| |||
| Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) | 5.171 | 0.5745 | |
| Proto-oncogene tyrosine-protein kinase LCK | 4.370 | 0.4370 | |
|
| Glucocorticoid receptor | 4.332 | 0.5415 |
| Glycogen synthase kinase-3 beta | 4.298 | 0.6140 | |
| Cathepsin B | 4.110 | 0.4566 | |
| Peroxisome proliferator-activated receptor alpha | 4.042 | 0.5053 | |
| Prothrombin | 3.988 | 0.6646 | |
|
| |||
| Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) | 3.660 | 0.4067 | |
|
| Proto-oncogene tyrosine-protein kinase LCK | 3.596 | 0.5137 |
| Prothrombin | 3.496 | 0.3885 | |
| Leukotriene A-4 hydrolase | 3.354 | 0.3727 | |
|
| |||
| Dual specificity mitogen-activated protein kinase kinase 1 (MPKK1) | 4.246 | 0.4718 | |
| Glucocorticoid receptor | 3.931 | 0.4913 | |
| Estrogen receptor | 3.728 | 0.5325 | |
| Leukocyte elastase | 3.709 | 0.4121 | |
|
| Protein kinase C theta type | 3.689 | 0.5270 |
| Glycogen synthase kinase-3 beta | 3.642 | 0.5203 | |
| Proto-oncogene tyrosine-protein kinase LCK | 3.626 | 0.6044 | |
| Mitogen-activated protein kinase 10 | 3.596 | 0.5137 | |
| Peroxisome proliferator-activated receptor alpha | 3.576 | 0.4470 | |
Screening anti-HIV targets over molecule docking of compounds 1–5.
| Compound number | Molecules docking results | ||
|---|---|---|---|
| Target name | Fit score | Norm fit score | |
| Androgen receptor | 4.294 | 0.7157 | |
|
| Gag-pol polyprotein | 4.281 | 0.3058 |
| Glucocorticoid receptor | 4.010 | 0.5012 | |
| Renin | 3.781 | 0.5401 | |
|
| |||
| Androgen receptor | 4.768 | 0.7947 | |
|
| Glucocorticoid receptor | 4.332 | 0.5415 |
| Renin | 4.121 | 0.5151 | |
|
| |||
| Gag-pol polyprotein | 3.549 | 0.2218 | |
|
| Androgen receptor | 3.359 | 0.4199 |
| Renin | 3.347 | 0.4183 | |
| Thymidine kinase | 3.337 | 0.4171 | |
|
| |||
| Androgen receptor | 4.022 | 0.5028 | |
|
| Glucocorticoid receptor | 3.931 | 0.4913 |
| Gag-pol polyprotein | 3.674 | 0.2625 | |
| Protease | 3.556 | 0.4446 | |